The adipose tissue production of adiponectin is increased in end-stage renal disease

Cantarin, Maria P. Martinez; Waldman, Scott A.; Doria, Cataldo; Frank, Adam M.; Maley, Warren R.; Ramirez, Carlo B.; Keith, Scott W.; Falkner, Bonita

doi:10.1038/ki.2012.421

Cited by 59 publications

(55 citation statements)

References 35 publications

(43 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The upregulation of the adiponectin production rate as a compensatory mechanism to mitigate further renal injury appears to be the main cause of increased serum adiponectin levels in patients with advanced albuminuria. As mentioned above, the elevation of adiponectin expression and production in the setting of human renal disease has been demonstrated only in patients with end-stage renal disease (Martinez Cantarin et al 2013). Although, Komura et al (2010) reported that adiponectin production in the adipose tissue of subtotal nephrectomised mice did not change at 1 month after operation, the time duration of 1 month may be too short to elicit a full-blown upregulation of adiponectin production.…”

Section: Serum Adiponectin Levels In Patients With Albuminuriamentioning

confidence: 97%

“…Thus, in patients with increased UAE or decreased GFR, the adiponectin production rate -hepatic adiponectin excretion rateappears to be increased. This elevation could be attributed to an increased rate of adiponectin production, because adiponectin expression and adiponectin protein content in visceral as well as subcutaneous adipose tissue were found to be increased in patients with end-stage renal disease (Martinez Cantarin et al 2013). Studies investigating the possible modulation of hepatic adiponectin excretion rate in patients with renal disease are lacking, and thus further studies investigating this issue are needed.…”

Section: Urinary Adiponectin Excretion Rate In Patients With Albuminuriamentioning

confidence: 99%

See 1 more Smart Citation

The role of adiponectin in renal physiology and development of albuminuria

Christou¹,

Kiortsis²

2014

Journal of Endocrinology

View full text Add to dashboard Cite

Adiponectin is secreted by the adipose tissue and is downregulated in states of obesity and insulin resistance. There is a growing body of evidence indicating that adiponectin has renoprotective effects and protects against the development of albuminuria in rodent experiments. Adiponectin crossing the glomerular filtration barrier possibly inhibits inflammation, fibrosis and oxidative stress in kidneys through activation of AMP-activated protein kinase. Moreover, microalbuminuria is a well established early sign of progressive cardiovascular and renal disease, even in subjects with preserved glomerular filtration rate. Studies investigating the relationship between serum adiponectin levels and urinary albumin excretion rate (UAE) have yielded conflicting data and the mechanisms underlying the interplay between adiponectin and albuminuria remain to be elucidated. This article constitutes a critical review attempting to clarify any remaining confusion about this matter. Furthermore, this article examines the clinical significance of adiponectin-albuminuria interplay, suggesting that adiponectin is possibly involved in the development of albuminuria that is associated with obesity, diabetes and cardiovascular disease and may mediate, at least in part, the actions of medical treatments that influence UAE, such as angiotensin-converting-enzyme inhibitors, angiotensin II receptor blockers, thiazolidinediones, fenofibrate and diet. Further studies to investigate more thoroughly the renoprotective role of adiponectin in the human setting should be carefully planned, focusing on causality and the possible influence of adiponectin on the development of albuminuria in specific clinical settings.

show abstract

Section: Serum Adiponectin Levels In Patients With Albuminuriamentioning

confidence: 97%

Section: Urinary Adiponectin Excretion Rate In Patients With Albuminuriamentioning

confidence: 99%

The role of adiponectin in renal physiology and development of albuminuria

Christou¹,

Kiortsis²

2014

Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…51 According to Cantarin and coworkers, increased plasma adiponectin levels observed in ESRD are accompanied by an increase in adiponectin protein and mRNA expression in human subcutaneous and visceral adipose tissues, suggesting that there is a stimulus to produce more adiponectin protein despite elevated plasma levels. 52 A recent study demonstrated that there is higher expression of AdipoR1 in muscle tissue of ESRD patients compared to controls with normal kidney function. 53 Increased adiponectin production and increased AdipoR1 receptor expression, despite increased adiponectin levels, indicate that uremia confers adiponectin resistance.…”

Section: Circulating Adiponectin Levels In Esrd Patientsmentioning

confidence: 99%

“…67,68 In visceral fat and muscle of ESRD patients, AdipoR1 mRNA expression is increased, whereas expression of AdipoR2 is not modified by uremia. 52 Thus, adiponectin resistance with high levels of adiponectin but relatively low AdipoR2 may contribute to an impairment of adiponectin-stimulated fatty acid oxidation and lead to insulin resistance.…”

Section: Adiponectin and Insulin Resistance In Esrdmentioning

confidence: 99%

“…Alternatively, factors contained in the uremic and the proinflammatory environment may block the adiponectin signal transduction pathway, conferring adiponectin resistance. 52,53 Since AdipoR2 is the receptor involved in the inhibition of oxidative stress and inflammation, 22 adiponectin resistance with high levels of adiponectin but relatively low AdipoR2 may contribute to the inflammatory state seen in ESRD patients.…”

Section: Adiponectin and Inflammation In Esrdmentioning

confidence: 99%

See 1 more Smart Citation

Adiponectin and end-stage renal disease

Markaki¹,

Psylinakis²,

Spyridaki³

2016

View full text Add to dashboard Cite

Adiponectin (ADPN) is an adipokine with significant anti-inflammatory, insulin-sensitizing and anti-atherogenic properties, which is generally associated with a beneficial cardiometabolic profile. Paradoxically, end-stage renal disease (ESRD) is characterized by markedly increased plasma ADPN levels and increased cardiovascular risk. In spite of the cardioprotective properties attributed to adiponectin, cardiovascular complications remain the main cause of mortality in the ESRD population. Furthermore, these patients have enhanced chronic inflammation, increased insulin resistance and persistent protein-energy wasting. Studies of the impact of ADPN on clinical outcomes among ESRD patients have so far yielded contradictory results. This review article summarizes the current knowledge on ADPN functions and explores the role of ADPN in ESRD patients, with specific focus on inflammation, insulin resistance, cardiovascular disease and wasting.

show abstract

Adiponectin and the risk of gastrointestinal cancers in East Asians: Mendelian randomization analysis

Jiang

Wang

et al. 2022

Cancer Medicine

View full text Add to dashboard Cite

Background Adiponectin is an important adipocytokine and has been associated with the risks of gastrointestinal cancers (GICs). Mendelian randomization (MR) analysis is needed to assess the causal relationships between adiponectin and GICs. Methods We retrieved the summary data of genome‐wide association studies for adiponectin and six types of GICs in East Asians. A series of quality control steps were performed to select the eligible genetic instrumental tools. Horizontal pleiotropy and between‐SNP heterogeneity were tested to choose the primary MR method. We also conducted sensitivity analyses to test the robustness of the main findings. Results We detected neither heterogeneity nor horizontal pleiotropy for the eligible SNPs in all of the MR analyses. Inverse variance weighted (IVW) was therefore used as the primary method, and suggested that per 10% increase in log‐transformed adiponectin level was significantly associated with a decreased risk of gastric cancer (odds ratio [OR] = 0.88, 95% CI 0.81, 0.96), whereas with an increased risk of hepatocellular carcinoma (OR = 1.26, 95% CI 1.09, 1.44) and of biliary tract cancer (OR = 1.54, 95% CI 1.12, 2.12). However, only the association between adiponectin and HCC risk was statistically significant after correction for multiple testing. No statistically significant association was detected between adiponectin and esophageal (OR = 1.05, 95% CI 0.89, 1.23), pancreatic (OR = 1.04, 95% CI 0.78, 1.37), and colorectal cancers (OR = 1.00, 95% CI 0.93, 1.07). Sensitivity analyses did not find contradictory results. Conclusion High level of adiponectin may have a causal effect on and can serve as a biomarker for the carcinogenesis of gastric cancer, hepatocellular carcinoma, and biliary tract cancer.

show abstract

The adipose tissue production of adiponectin is increased in end-stage renal disease

Cited by 59 publications

References 35 publications

The role of adiponectin in renal physiology and development of albuminuria

The role of adiponectin in renal physiology and development of albuminuria

Adiponectin and end-stage renal disease

Adiponectin and the risk of gastrointestinal cancers in East Asians: Mendelian randomization analysis

Contact Info

Product

Resources

About